Skip to content

the Association of Intestinal Microbial Metabolites and Cardiac Function in Acute Myocardial Infarction

the Association of Intestinal Microbial Metabolites and Cardiac Function in Acute Myocardial Infarction

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04955054
Enrollment
100
Registered
2021-07-08
Start date
2020-10-11
Completion date
2025-12-31
Last updated
2021-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Myocardial Infarction

Keywords

bile acids, short chain fatty acid, cardiac function

Brief summary

Recently, more and more studies have confirmed that intestinal flora is closely related to the occurrence and development of cardiovascular diseases.Bile acids (BAS), short chain fatty acids (SCFA) and trimethylamine oxide (TMAO), the main metabolites of intestinal flora, are the key mediators of the interaction between gut and host. We aim to explore the association of BAs and SCFA with cardiac function in patients with AMI.

Detailed description

Cardiovascular disease is the leading cause of death in China, and acute myocardial infarction (AMI) is the main cause of death of cardiovascular disease. In recent years, clinical epidemiological studies have confirmed that intestinal flora is closely related to the occurrence and development of cardiovascular diseases such as diabetes, hyperlipidemia, hypertension, atherosclerosis, coronary heart disease, heart failure and so on. Bile acids (BAS), short chain fatty acids (SCFA) and trimethylamine oxide (TMAO), the main metabolites of intestinal flora, are the key mediators of the interaction between gut and host. It is suggested that intestinal flora and its metabolites participate in the pathophysiological process of cardiovascular disease through inflammation, oxidative stress and programmed death, and have the potential to be intervention targets. Basic and clinical studies have shown that TMAO is associated with the onset and poor prognosis of AMI by promoting the development of atherosclerosis and thrombosis, but there are few reports on the relationship between BAs or SCFA and AMI. We aim to explore the association of BAs and SCFA with cardiac function in patients with AMI.

Interventions

DIAGNOSTIC_TESTdiagnose

Patients from UAP and AMI meet the criteria of UAP or STEMI.

Sponsors

Peking University Third Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
Yes

Inclusion criteria

The patient, aged 18-85 years, had undergone coronary angiography and agreed to be enrolled and signed the informed consent. AMI : according to ST segment elevation myocardial infarction diagnostic criteria. UAP: 1. typical chest pain symptoms; 2. negative in markers of myocardial injury; 3. The stenosis of main coronary artery or its main branches is more than 50% Control: 1. atypical chest pain symptoms 2. negative in markers of myocardial injury; 3. The stenosis of main coronary artery and its main branches is less than 50%

Exclusion criteria

1. Acute infection or application of antibiotics in the past 3 months; 2. Chronic heart failure; 3. History of inflammatory or absorptive bowel disease and bowel resection; 4. Acute, chronic liver disease or other reasons lead to abnormal liver function (transaminase is more than 5 times of normal value); 5. Renal insufficiency (serum creatinine \> 220μml/L or creatinine clearance rate \< 30 ml/min); 6. Malignant tumor; 7. Autoimmune diseases; 8. Uninformed patients

Design outcomes

Primary

MeasureTime frameDescription
the plasma levels of BAs and SCFAone weekthe plasma levels of bile acids and short chain fatty acid in fast

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026